文献速递新发突发、热带与寄生虫病

KAF156在恶性疟原虫人体感染试验中的安全性、药代动力学和因果预防效力

Safety, Pharmacokinetics, and Causal Prophylactic Efficacy of KAF156 in a Plasmodium falciparum Human Infection Study.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该研究在受控人类疟疾感染(CHMI)模型中评估新型抗疟药KAF156的因果预防效力。结果显示KAF156安全耐受,感染前给药800 mg全部受试者获得保护,感染后给药800、300、100 mg全部受保护,50 mg保护14例中3例,20 mg及安慰剂均未保护。暴露-反应分析提示给药后24小时浓度21.5 ng/mL(90%CI 17.66-25.32)可确保95%保护概率。

要点

  • KAF156在CHMI前或后给药均显示高保护效力。
  • 800、300、100 mg剂量在感染后给药可完全保护。
  • 24小时血药浓度21.5 ng/mL与95%保护概率相关。

核心结论

  • KAF156安全且耐受性良好,在CHMI前后均展示高保护效力。

研究设计与样本

  • 在健康无疟疾志愿者中开展CHMI研究,第一部分感染前3小时给800 mg KAF156或安慰剂,第二部分感染后21小时给800、300、100、50、20 mg单剂,每队列7-14例接受KAF156、至多4例接受安慰剂。

主要发现

  • 所有剂量水平KAF156安全耐受,报告2例严重不良事件均痊愈且与KAF156无关。
  • 第一部分KAF156组全部受保护,安慰剂组无一保护。
  • 第二部分安慰剂及20 mg组全部感染,50 mg组14例中3例受保护,800、300、100 mg组全部受保护。
  • 暴露-反应分析提示给药后24小时浓度21.5 ng/mL(90%CI 17.66-25.32)可确保95%保护概率。

关键数值与推荐

  • 24小时给药后KAF156浓度21.5 ng/mL(90%CI 17.66-25.32 ng/mL)对应95%保护概率。

临床怎么用

  • KAF156可作为疟疾因果预防的候选药物,需关注暴露-反应关系以指导剂量选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: KAF156 is a novel antimalarial drug that is active against both liver- and blood-stage Plasmodium parasites, including drug-resistant strains. Here, we investigated the causal prophylactic efficacy of KAF156 in a controlled human malaria infection (CHMI) model. METHODS: In part 1, healthy, malaria-naive participants received 800 mg KAF156 or placebo 3 hours before CHMI with P. falciparum-infected mosquitoes. In part 2, KAF156 was administered as single doses of 800, 300, 100, 50, or 20 mg 21 hours post-CHMI. All participants received atovaquone/proguanil treatment if blood-stage infection was detected or on day 29. For each cohort, 7-14 subjects were enrolled to KAF156 treatment and up to 4 subjects to placebo. RESULTS: KAF156 at all dose levels was safe and well tolerated. Two serious adverse events were reported-both resolved without sequelae and neither was considered related to KAF156. In part 1, all participants treated with KAF156 and none of those randomized to placebo were protected against malaria infection. In part 2, all participants treated with placebo or 20 mg KAF156 developed malaria infection. In contrast, 50 mg KAF156 protected 3 of 14 participants from infection, and doses of 800, 300, and 100 mg KAF156 protected all subjects against infection. An exposure-response analysis suggested that a 24-hour postdose concentration of KAF156 of 21.5 ng/mL (90% confidence interval, 17.66-25.32 ng/mL) would ensure a 95% chance of protection from malaria parasite infection. CONCLUSIONS: KAF156 was safe and well tolerated and demonstrated high levels of pre- and post-CHMI protective efficacy. CLINICAL TRIALS REGISTRATION: NCT04072302.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Kublin JG, Murphy SC, Maenza J, et al. Safety, Pharmacokinetics, and Causal Prophylactic Efficacy of KAF156 in a Plasmodium falciparum Human Infection Study. Clin Infect Dis. 2021. PMID: 32644127. doi:10.1093/cid/ciaa952

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。